表紙
市場調査レポート

乳癌:パイプライン製品の分析

Breast Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 229715
出版日 ページ情報 英文 2995 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
乳癌:パイプライン製品の分析 Breast Cancer - Pipeline Review, H2 2015
出版日: 2015年12月31日 ページ情報: 英文 2995 Pages
概要

乳癌は、乳腺細胞から発症する癌の一種です。通常、乳管の内壁や小葉から始まります。乳癌の危険因子として、年齢、初潮が早い、閉経が遅い、太り過ぎ、ホルモン補充療法、経口避妊薬の使用、アルコール摂取などが挙げられます。症状は、乳房のしこり、乳房の大きさや形状の変化、乳頭からの分泌物などです。治療には、放射線、腫瘍摘出手術、乳腺切除術、化学療法、ホルモン療法などが含まれます。

当レポートでは、乳癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

乳癌の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6820IDB

Summary

Global Markets Direct's, 'Breast Cancer - Pipeline Review, H2 2015', provides an overview of the Breast Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Breast Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Breast Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Breast Cancer Overview
  • Therapeutics Development
  • Breast Cancer - Therapeutics under Development by Companies
  • Breast Cancer - Therapeutics under Investigation by Universities/Institutes
  • Breast Cancer - Pipeline Products Glance
  • Breast Cancer - Products under Development by Companies
  • Breast Cancer - Products under Investigation by Universities/Institutes
  • Breast Cancer - Companies Involved in Therapeutics Development
  • Breast Cancer - Therapeutics Assessment
  • Drug Profiles
  • Breast Cancer - Recent Pipeline Updates
  • Breast Cancer - Dormant Projects
  • Breast Cancer - Discontinued Products
  • Breast Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Breast Cancer, H2 2015
  • Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Development by Companies, H2 2015 (Contd..9)
  • Number of Products under Development by Companies, H2 2015 (Contd..10)
  • Number of Products under Development by Companies, H2 2015 (Contd..11)
  • Number of Products under Development by Companies, H2 2015 (Contd..12)
  • Number of Products under Development by Companies, H2 2015 (Contd..13)
  • Number of Products under Development by Companies, H2 2015 (Contd..14)
  • Number of Products under Development by Companies, H2 2015 (Contd..15)
  • Number of Products under Development by Companies, H2 2015 (Contd..16)
  • Number of Products under Development by Companies, H2 2015 (Contd..17)
  • Number of Products under Development by Companies, H2 2015 (Contd..18)
  • Number of Products under Development by Companies, H2 2015 (Contd..19)
  • Number of Products under Development by Companies, H2 2015 (Contd..20)
  • Number of Products under Development by Companies, H2 2015 (Contd..21)
  • Number of Products under Development by Companies, H2 2015 (Contd..22)
  • Number of Products under Development by Companies, H2 2015 (Contd..23)
  • Number of Products under Development by Companies, H2 2015 (Contd..24)
  • Number of Products under Development by Companies, H2 2015 (Contd..25)
  • Number of Products under Development by Companies, H2 2015 (Contd..26)
  • Number of Products under Development by Companies, H2 2015 (Contd..27)
  • Number of Products under Development by Companies, H2 2015 (Contd..28)
  • Number of Products under Development by Companies, H2 2015 (Contd..29)
  • Number of Products under Development by Companies, H2 2015 (Contd..30)
  • Number of Products under Development by Companies, H2 2015 (Contd..31)
  • Number of Products under Development by Companies, H2 2015 (Contd..32)
  • Number of Products under Development by Companies, H2 2015 (Contd..33)
  • Number of Products under Development by Companies, H2 2015 (Contd..34)
  • Number of Products under Development by Companies, H2 2015 (Contd..35)
  • Number of Products under Development by Companies, H2 2015 (Contd..36)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..7)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Development by Companies, H2 2015 (Contd..13)
  • Products under Development by Companies, H2 2015 (Contd..14)
  • Products under Development by Companies, H2 2015 (Contd..15)
  • Products under Development by Companies, H2 2015 (Contd..16)
  • Products under Development by Companies, H2 2015 (Contd..17)
  • Products under Development by Companies, H2 2015 (Contd..18)
  • Products under Development by Companies, H2 2015 (Contd..19)
  • Products under Development by Companies, H2 2015 (Contd..20)
  • Products under Development by Companies, H2 2015 (Contd..21)
  • Products under Development by Companies, H2 2015 (Contd..22)
  • Products under Development by Companies, H2 2015 (Contd..23)
  • Products under Development by Companies, H2 2015 (Contd..24)
  • Products under Development by Companies, H2 2015 (Contd..25)
  • Products under Development by Companies, H2 2015 (Contd..26)
  • Products under Development by Companies, H2 2015 (Contd..27)
  • Products under Development by Companies, H2 2015 (Contd..28)
  • Products under Development by Companies, H2 2015 (Contd..29)
  • Products under Development by Companies, H2 2015 (Contd..30)
  • Products under Development by Companies, H2 2015 (Contd..31)
  • Products under Development by Companies, H2 2015 (Contd..32)
  • Products under Development by Companies, H2 2015 (Contd..33)
  • Products under Development by Companies, H2 2015 (Contd..34)
  • Products under Development by Companies, H2 2015 (Contd..35)
  • Products under Development by Companies, H2 2015 (Contd..36)
  • Products under Development by Companies, H2 2015 (Contd..37)
  • Products under Development by Companies, H2 2015 (Contd..38)
  • Products under Development by Companies, H2 2015 (Contd..39)
  • Products under Development by Companies, H2 2015 (Contd..40)
  • Products under Development by Companies, H2 2015 (Contd..41)
  • Products under Development by Companies, H2 2015 (Contd..42)
  • Products under Development by Companies, H2 2015 (Contd..43)
  • Products under Development by Companies, H2 2015 (Contd..44)
  • Products under Development by Companies, H2 2015 (Contd..45)
  • Products under Development by Companies, H2 2015 (Contd..46)
  • Products under Development by Companies, H2 2015 (Contd..47)
  • Products under Development by Companies, H2 2015 (Contd..48)
  • Products under Development by Companies, H2 2015 (Contd..49)
  • Products under Development by Companies, H2 2015 (Contd..50)
  • Products under Development by Companies, H2 2015 (Contd..51)
  • Products under Development by Companies, H2 2015 (Contd..52)
  • Products under Development by Companies, H2 2015 (Contd..53)
  • Products under Development by Companies, H2 2015 (Contd..54)
  • Products under Development by Companies, H2 2015 (Contd..55)
  • Products under Development by Companies, H2 2015 (Contd..56)
  • Products under Development by Companies, H2 2015 (Contd..57)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..11)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..12)
  • Breast Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015
  • Breast Cancer - Pipeline by 4SC AG, H2 2015
  • Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H2 2015
  • Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
  • Breast Cancer - Pipeline by AB Science SA, H2 2015
  • Breast Cancer - Pipeline by AbbVie Inc., H2 2015
  • Breast Cancer - Pipeline by AbGenomics International, Inc., H2 2015
  • Breast Cancer - Pipeline by Ability Pharma, SL, H2 2015
  • Breast Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015
  • Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
  • Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
  • Breast Cancer - Pipeline by Adaptimmune Limited, H2 2015
  • Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2015
  • Breast Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
  • Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2015
  • Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2015
  • Breast Cancer - Pipeline by Advaxis, Inc., H2 2015
  • Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
  • Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H2 2015
  • Breast Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H2 2015
  • Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H2 2015
  • Breast Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015
  • Breast Cancer - Pipeline by Affichem SA, H2 2015
  • Breast Cancer - Pipeline by Agilvax, Inc., H2 2015
  • Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2015
  • Breast Cancer - Pipeline by Alchemia Limited, H2 2015
  • Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
  • Breast Cancer - Pipeline by Almac Discovery Limited, H2 2015
  • Breast Cancer - Pipeline by Amarna Therapeutics B.V., H2 2015
  • Breast Cancer - Pipeline by Ambrx, Inc., H2 2015
  • Breast Cancer - Pipeline by Amgen Inc., H2 2015
  • Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015
  • Breast Cancer - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2015
  • Breast Cancer - Pipeline by AngioGenex, Inc., H2 2015
  • Breast Cancer - Pipeline by Angion Biomedica Corp., H2 2015
  • Breast Cancer - Pipeline by ANP Technologies, Inc., H2 2015
  • Breast Cancer - Pipeline by AntiCancer, Inc., H2 2015
  • Breast Cancer - Pipeline by Antigen Express, Inc., H2 2015
  • Breast Cancer - Pipeline by Antoxis Limited, H2 2015
  • Breast Cancer - Pipeline by Aphios Corporation, H2 2015
  • Breast Cancer - Pipeline by arGEN-X BV, H2 2015
  • Breast Cancer - Pipeline by Armour Therapeutics Inc., H2 2015
  • Breast Cancer - Pipeline by Arno Therapeutics, Inc., H2 2015
  • Breast Cancer - Pipeline by ArQule, Inc., H2 2015
  • Breast Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
  • Breast Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
  • Breast Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2015
  • Breast Cancer - Pipeline by AskAt Inc., H2 2015
  • Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
  • Breast Cancer - Pipeline by Astellas Pharma Inc., H2 2015
  • Breast Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Breast Cancer - Pipeline by AstraZeneca Plc, H2 2015

List of Figures

  • Number of Products under Development for Breast Cancer, H2 2015
  • Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top